Medicine overview
Indications of Gestop 28
Gestop 28 is a combined oral contraceptive (COC) tablet containing an estrogen (ethinylestradiol) and a third-generation progestin (gestodene).
Established/Approved Uses
- Prevention of pregnancy (contraception) in women of reproductive age who choose a combined hormonal method
Guideline-Supported/Adjunct Uses
- Regulation of irregular or heavy menstrual cycles in women who also desire contraception
- Management of functional (non-neoplastic) ovarian cysts as an adjunct, in conjunction with a physician's evaluation
- Adjunct management of hormonally-responsive acne or mild hirsutism in women who also desire contraception (not a first-line indication)
Gestop 28 is used solely as directed by a physician; it does not protect against sexually transmitted infections.
Composition
Each tablet of Ethinylestradiol + Gestodene typically contains Ethinylestradiol 20-30 micrograms and Gestodene 0.05-0.075 mg, depending on the specific formulation (monophasic or triphasic pack). Each pack usually supplies 21 active tablets, sometimes with an additional 7 inactive/placebo tablets to complete a 28-day cycle. Exact strengths, phasing, and pack size may vary by manufacturer and market; refer to the specific product label for the strength dispensed.
Description
Gestop 28 is a combined oral contraceptive (COC) that pairs ethinylestradiol, a synthetic estrogen, with gestodene, a highly potent third-generation synthetic progestin derived from 19-nortestosterone. As a fixed-dose combination tablet taken once daily, Gestop 28 works primarily by suppressing ovulation and is one of the most widely studied classes of hormonal contraceptives worldwide.
Therapeutic Class
Gestop 28 belongs to the Combined Hormonal Contraceptive class - specifically an estrogen-progestin combined oral contraceptive (COC) pairing an estrogen (ethinylestradiol) with a third-generation progestin (gestodene).
Pharmacology
Pharmacodynamics
Ethinylestradiol + Gestodene prevents pregnancy mainly by suppressing the hypothalamic-pituitary-ovarian axis, which inhibits the mid-cycle luteinizing hormone (LH) surge and thereby prevents ovulation. The gestodene component also thickens cervical mucus (impeding sperm penetration) and produces an endometrium less receptive to implantation, while the ethinylestradiol component stabilizes the endometrium and helps regulate the menstrual cycle.
Pharmacokinetics
- Absorption: Both components are rapidly and almost completely absorbed after oral administration; gestodene has essentially 100% bioavailability due to minimal first-pass metabolism.
- Distribution: Gestodene is highly bound to sex hormone-binding globulin (SHBG) and albumin; ethinylestradiol is highly bound to albumin.
- Metabolism: Both components are extensively metabolized in the liver, principally via hepatic cytochrome P450 (CYP3A4) pathways.
- Elimination: Metabolites are excreted in urine and feces; the elimination half-life of gestodene is approximately 12-15 hours and of ethinylestradiol approximately 20-24 hours.
Dosage & Administration of Gestop 28
Gestop 28 is taken by mouth once daily, at approximately the same time each day, following the schedule below.
| Indication/Population | Dose | Notes |
|---|---|---|
| Adults - contraception (21-day pack) | One tablet daily for 21 consecutive days, then a 7-day tablet-free interval before starting the next pack | Start on day 1 of the menstrual cycle for immediate protection; a withdrawal bleed usually occurs during the tablet-free interval |
| Adults - contraception (28-day pack) | One active tablet daily for 21 days followed by 7 inactive tablets, then start the next pack immediately with no break | Helps maintain the daily habit; inactive tablets contain no hormone |
| Missed pill (less than 24 hours late) | Take the missed tablet as soon as remembered, then continue the pack as usual | Contraceptive protection is generally maintained |
| Missed pill (more than 24 hours late) | Take the most recent missed tablet as soon as remembered and continue the pack; use a barrier method (e.g., condoms) for the next 7 days | Follow the patient information leaflet or consult a physician/pharmacist for the specific missed-pill rule that applies |
| Renal or hepatic impairment | Not recommended in significant hepatic impairment (see Contraindications) | No well-established dose adjustment for renal impairment; use with caution |
| Children (pre-menarche) | Not applicable | Not indicated before menarche (see Pediatric Uses) |
Tablets should be swallowed whole with water and may be taken with or without food. If vomiting or severe diarrhea occurs within a few hours of taking a tablet, absorption may be incomplete and the missed-pill instructions above should be followed.
Administration of Gestop 28
Gestop 28 tablets should be taken by mouth at approximately the same time every day to maintain steady hormone levels and maximize contraceptive reliability. Tablets should be swallowed whole with water, with or without food, and taken in the order indicated on the blister pack. See Dosage and Administration for the full schedule and missed-pill guidance.
Interaction of Gestop 28
Gestop 28 has clinically significant interactions with the following medicines:
| Interacting Drug/Class | Mechanism | Clinical Consequence |
|---|---|---|
| Hepatic enzyme inducers (e.g., rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital, primidone, topiramate, St. John's Wort) | Induction of hepatic CYP3A4 enzymes increases metabolism of ethinylestradiol and gestodene | Reduced contraceptive efficacy and breakthrough bleeding; an additional barrier method is usually advised during and after use of the inducer |
| Certain HIV protease inhibitors and some non-nucleoside reverse transcriptase inhibitors (e.g., ritonavir-boosted regimens) | Alteration of hepatic metabolism of the contraceptive steroids | May reduce or, less commonly, increase contraceptive hormone levels; efficacy and safety may be affected - alternative or additional contraception advised |
| Lamotrigine | Gestop 28 induces hepatic glucuronidation of lamotrigine | Significantly reduced lamotrigine plasma levels, risking loss of seizure control; dose adjustment of lamotrigine may be needed under specialist supervision, particularly during the hormone-free interval |
| Broad-spectrum antibiotics (general) | Theoretical alteration of enterohepatic recirculation/gut flora | Evidence of reduced efficacy is limited except for rifampicin/rifabutin; nonetheless, some prescribers advise additional precautions during short-term antibiotic courses |
| Ciclosporin | Gestop 28 may inhibit metabolism of ciclosporin | Increased ciclosporin plasma levels; monitor for toxicity |
Contraindications
- Known hypersensitivity to Ethinylestradiol + Gestodene or any component of the formulation
- Confirmed or suspected pregnancy
- Current or past history of venous thromboembolism (deep vein thrombosis or pulmonary embolism)
- Current or past history of arterial thromboembolic disease (e.g., myocardial infarction, stroke, transient ischemic attack)
- Known thrombogenic mutations (e.g., Factor V Leiden, prothrombin mutation, protein C/S or antithrombin deficiency)
- Migraine with focal aura
- Uncontrolled severe hypertension
- Diabetes mellitus with vascular involvement
- Known or suspected breast cancer or other known or suspected estrogen-dependent malignancy
- Hepatic adenoma, hepatocellular carcinoma, or severe active liver disease with abnormal liver function
- Undiagnosed abnormal vaginal bleeding
- History of cholestatic jaundice related to prior combined hormonal contraceptive use or pregnancy
- Heavy smoking (15 or more cigarettes/day) in women over 35 years of age
See Precautions and Warnings for additional cautions and relative risk factors that require individualized assessment rather than an absolute contraindication.
Side Effects of Gestop 28
Common
- Nausea, occasionally vomiting (especially in early cycles)
- Breast tenderness (mastodynia)
- Headache
- Breakthrough bleeding or spotting between periods
- Mood changes
- Weight change
Uncommon
- Decreased libido
- Chloasma (facial skin pigmentation)
- Fluid retention/mild edema
- Contact lens intolerance
- Amenorrhea after stopping Gestop 28
Rare/Serious
- Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - see Precautions and Warnings
- Arterial thromboembolism (stroke, myocardial infarction)
- Hepatic adenoma or, rarely, hepatocellular carcinoma
- Gallbladder disease
- Severe hypersensitivity reactions
- Worsening of hypertension
Patients should seek prompt medical attention for signs of a blood clot (leg swelling/pain, sudden chest pain or breathlessness, sudden severe headache, visual disturbance, or weakness on one side of the body) while taking Gestop 28.
Pregnancy & Lactation
Pregnancy
Gestop 28 is contraindicated in pregnancy; it is not indicated for use once pregnancy is confirmed or suspected and offers no benefit in that setting, so it should be discontinued immediately if pregnancy occurs or is suspected, and a physician consulted. Although available data do not clearly demonstrate fetal harm from inadvertent early exposure, Gestop 28 should only ever be used to prevent pregnancy, not during it.
Lactation
Gestop 28 is generally not recommended during breastfeeding, particularly in the first few weeks postpartum, because the estrogen component can reduce the quantity and alter the composition of breast milk. A physician should be consulted; a progestin-only contraceptive is often preferred for breastfeeding women who need hormonal contraception, use only if clearly needed and if the potential benefit justifies the potential risk to the infant.
Precautions & Warnings
Venous Thromboembolism (VTE) Risk
All combined oral contraceptives, including Gestop 28, increase the risk of venous thromboembolism (DVT/PE) compared with non-use. Some epidemiological studies suggest that third-generation progestins such as gestodene may carry a modestly higher VTE risk than second-generation progestins (e.g., levonorgestrel); this remains an area of ongoing study, and an individualized risk assessment (age, smoking, obesity, family history, immobility, recent surgery) is recommended before and during use of Gestop 28.
Arterial Thromboembolism Risk
Gestop 28 may increase the risk of stroke and myocardial infarction, particularly in women who smoke, are over 35 years of age, or have hypertension, diabetes, migraine, or other cardiovascular risk factors.
Smoking
Cigarette smoking increases the risk of serious cardiovascular adverse effects with combined oral contraceptive use; this risk increases with age and with the number of cigarettes smoked, and is significant in women over 35 years (see Contraindications).
Blood Pressure and Metabolic Effects
Blood pressure should be monitored periodically, as Gestop 28 may raise blood pressure in some users. Gestop 28 may also have modest effects on carbohydrate and lipid metabolism; use with caution in women with diabetes or dyslipidemia.
Hepatic Effects
Gestop 28 should be discontinued if jaundice, hepatic adenoma, or significant liver dysfunction develops.
Other Precautions
- Does not protect against sexually transmitted infections, including HIV.
- Migraine or unusually severe headache developing for the first time, or worsening migraine, warrants discontinuation and medical evaluation.
- New visual disturbances (e.g., diplopia, vision loss) warrant discontinuation and prompt evaluation.
- Chloasma may occur, especially with sun exposure.
- Regular physical examinations, including blood pressure checks and cervical/breast screening as clinically indicated, are recommended during long-term use.
Overdose Effects of Gestop 28
No serious adverse effects have been consistently reported from acute overdose of Gestop 28. Overdose may cause nausea, vomiting, breast tenderness, dizziness, or withdrawal-type vaginal bleeding in females; young children who accidentally ingest tablets may experience nausea/vomiting or, rarely, withdrawal bleeding-like spotting. There is no specific antidote.
If an overdose of Gestop 28 is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive and symptomatic and should be provided by trained medical personnel; do not attempt specific home treatment.
Storage Conditions
Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.
Use In Special Populations
Hepatic Impairment
Gestop 28 is contraindicated in women with severe active liver disease, hepatic adenoma, or hepatocellular carcinoma (see Contraindications); use with caution in milder hepatic impairment.
Renal Impairment
No well-established dose adjustment is defined; use with caution and physician oversight.
Smokers and Women Over 35
Combined use of Gestop 28 with heavy smoking in women over 35 years is contraindicated due to increased cardiovascular risk (see Contraindications).
Obesity
Obesity is an independent risk factor for venous thromboembolism; individualized risk-benefit assessment is recommended before prescribing Gestop 28 to obese women.
Pregnancy and Lactation
See Pregnancy and Lactation section for full details.
Children and Adolescents
See Pediatric Uses section for full details.
Elderly
Gestop 28 is not indicated in postmenopausal women, as it is a contraceptive intended for women of reproductive age.
Duration Of Treatment
Gestop 28 may be used continuously, cycle after cycle, for as long as contraception is desired and no contraindications or new risk factors develop. A physician should periodically reassess the ongoing suitability of Gestop 28 (e.g., at routine annual visits), taking into account changes in age, blood pressure, smoking status, migraine history, and other cardiovascular risk factors, and should provide guidance on when to stop, for example when planning pregnancy or approaching menopause.
Drug Classes
Ethinylestradiol + Gestodene belongs to the Combined Oral Contraceptive (estrogen + progestin) class, pairing ethinylestradiol with the third-generation progestin gestodene, alongside other combined oral contraceptives such as ethinylestradiol/levonorgestrel and ethinylestradiol/desogestrel.
Mode Of Action
Ethinylestradiol + Gestodene works mainly by suppressing the pituitary release of luteinizing hormone (LH), thereby preventing ovulation; it additionally thickens cervical mucus to impede sperm transport and produces an endometrial lining less favorable to implantation. See Pharmacology for full pharmacodynamic and pharmacokinetic details.
Pregnancy
X
Pediatric Uses
Gestop 28 is not indicated before menarche. In postmenarcheal adolescents who require contraception, Gestop 28 may be used following the same dosing as adults, but safety and efficacy in adolescents younger than the age at which regular ovulatory cycles are established have not been specifically studied, and use in very young adolescents is generally not recommended. A physician should evaluate individual risk factors, including migraine, cardiovascular risk, and thrombosis risk, before prescribing Gestop 28 to an adolescent.
Frequently Asked Questions
Q: What is Gestop 28 30 mcg+75 mcg Tablet used for?
A: Gestop 28 30 mcg+75 mcg Tablet is a combined oral contraceptive pill used primarily to prevent pregnancy. It may also be used, under a physician's guidance, to help regulate irregular menstrual cycles in women who also want contraception.
Q: How do I take Gestop 28 30 mcg+75 mcg Tablet?
A: Gestop 28 30 mcg+75 mcg Tablet is taken once daily, at about the same time each day, for 21 days followed by either a 7-day tablet-free interval or 7 inactive tablets, then the next pack is started. Taking it at a consistent time each day helps maintain reliable contraceptive protection.
Q: Who should not take Gestop 28 30 mcg+75 mcg Tablet?
A: Gestop 28 30 mcg+75 mcg Tablet should not be used by women who are pregnant, smoke heavily and are over 35 years old, have a current or past history of blood clots (DVT/PE), stroke, or heart attack, have migraine with aura, have uncontrolled high blood pressure, have certain liver tumors or severe liver disease, have hormone-sensitive cancer, or are hypersensitive to any component of the tablet.
Q: Does Gestop 28 30 mcg+75 mcg Tablet increase the risk of blood clots?
A: Yes. All combined oral contraceptives, including Gestop 28 30 mcg+75 mcg Tablet, increase the risk of venous thromboembolism (blood clots in the legs or lungs) compared with not using hormonal contraception. Some studies suggest gestodene-containing pills like Gestop 28 30 mcg+75 mcg Tablet may carry a somewhat higher clot risk than pills containing older (second-generation) progestins, so your physician will assess your individual risk factors, such as smoking, obesity, or family history of clots, before prescribing it.
Q: Can I take Gestop 28 30 mcg+75 mcg Tablet while breastfeeding?
A: Use of Gestop 28 30 mcg+75 mcg Tablet during breastfeeding is generally not recommended, especially in the early weeks after delivery, because the estrogen component can reduce breast milk supply. Please consult your physician, who may recommend a progestin-only option instead, and use Gestop 28 30 mcg+75 mcg Tablet only if clearly needed and the benefit outweighs the risk to your baby.
Q: What should I do if I miss a dose of Gestop 28 30 mcg+75 mcg Tablet or take too much?
A: If you miss a tablet of Gestop 28 30 mcg+75 mcg Tablet by less than 24 hours, take it as soon as you remember and continue the pack as usual. If it has been more than 24 hours, follow the missed-pill instructions in your package leaflet and use a barrier method such as condoms for the next 7 days. If you suspect you have taken too much Gestop 28 30 mcg+75 mcg Tablet, seek immediate medical attention or contact a poison control center/emergency services.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.
